The FDA has released plans for an expanded use of remote regulatory assessments (RRA). This method of review became invaluable in the midst of the pandemic. The FDA has determined it will continue to use RRAs not only for pandemic-related products, but more broadly. RRAs have proven to be both an effective way to perform certain assessments as well as an efficient way to manage resources.

Read the explanation here.